These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 17920893)

  • 1. Screening for hereditary breast cancer.
    Dent R; Warner E
    Semin Oncol; 2007 Oct; 34(5):392-400. PubMed ID: 17920893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of magnetic resonance imaging in screening women at high risk of breast cancer.
    Warner E
    Top Magn Reson Imaging; 2008 Jun; 19(3):163-9. PubMed ID: 18941396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma.
    Hartman AR; Daniel BL; Kurian AW; Mills MA; Nowels KW; Dirbas FM; Kingham KE; Chun NM; Herfkens RJ; Ford JM; Plevritis SK
    Cancer; 2004 Feb; 100(3):479-89. PubMed ID: 14745863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial.
    Kuhl C; Weigel S; Schrading S; Arand B; Bieling H; König R; Tombach B; Leutner C; Rieber-Brambs A; Nordhoff D; Heindel W; Reiser M; Schild HH
    J Clin Oncol; 2010 Mar; 28(9):1450-7. PubMed ID: 20177029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk.
    Podo F; Sardanelli F; Canese R; D'Agnolo G; Natali PG; Crecco M; Grandinetti ML; Musumeci R; Trecate G; Bergonzi S; De Simone T; Costa C; Pasini B; Manuokian S; Spatti GB; Vergnaghi D; Morassut S; Boiocchi M; Dolcetti R; Viel A; De Giacomi C; Veronesi A; Coran F; Silingardi V; Turchett D; Cortesi L; De Santis M; Federico M; Romagnoli R; Ferrari S; Bevilacqua G; Bartolozzi C; Caligo MA; Cilotti A; Marini C; Cirillo S; Marra V; Martincich L; Contegiacomo A; Pensabene M; Capuano I; Burgazzi GB; Petrillo A; Bonomo L; Carriero A; Mariani-Costantini R; Battista P; Cama A; Palca G; Di Maggio C; D'Andrea E; Bazzocchi M; Francescutti GE; Zuiani C; Londero V; Zunnui I; Gustavino C; Centurioni MG; Iozzelli A; Panizza P; Del Maschio A
    J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):115-24. PubMed ID: 12585665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition.
    Kriege M; Brekelmans CT; Boetes C; Muller SH; Zonderland HM; Obdeijn IM; Manoliu RA; Kok T; Rutgers EJ; de Koning HJ; Klijn JG;
    Cancer; 2006 Jun; 106(11):2318-26. PubMed ID: 16615112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic resonance imaging of the breast improves detection of invasive cancer, preinvasive cancer, and premalignant lesions during surveillance of women at high risk for breast cancer.
    Riedl CC; Ponhold L; Flöry D; Weber M; Kroiss R; Wagner T; Fuchsjäger M; Helbich TH
    Clin Cancer Res; 2007 Oct; 13(20):6144-52. PubMed ID: 17947480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
    Warner E; Plewes DB; Hill KA; Causer PA; Zubovits JT; Jong RA; Cutrara MR; DeBoer G; Yaffe MJ; Messner SJ; Meschino WS; Piron CA; Narod SA
    JAMA; 2004 Sep; 292(11):1317-25. PubMed ID: 15367553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early detection of breast and ovarian cancer in families with BRCA mutations.
    Vasen HF; Tesfay E; Boonstra H; Mourits MJ; Rutgers E; Verheyen R; Oosterwijk J; Beex L
    Eur J Cancer; 2005 Mar; 41(4):549-54. PubMed ID: 15737559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The "EVA" Trial: Evaluation of the Efficacy of Diagnostic Methods (Mammography, Ultrasound, MRI) in the secondary and tertiary prevention of familial breast cancer. Preliminary results after the first half of the study period].
    Kuhl CK; Schrading S; Weigel S; Nüssle-Kügele K; Sittek H; Arand B; Morakkabati N; Leutner C; Tombach B; Nordhoff D; Perlet C; Rieber A; Heindel W; Brambs HJ; Schild H
    Rofo; 2005 Jun; 177(6):818-27. PubMed ID: 15902631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI and mammography surveillance of women at increased risk for breast cancer: recommendations using an evidence-based approach.
    Granader EJ; Dwamena B; Carlos RC
    Acad Radiol; 2008 Dec; 15(12):1590-5. PubMed ID: 19000876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI screening in a clinic population with a family history of breast cancer.
    Yu J; Park A; Morris E; Liberman L; Borgen PI; King TA
    Ann Surg Oncol; 2008 Feb; 15(2):452-61. PubMed ID: 18026801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI in breast cancer management: potential for benefit and harm.
    Jatoi I
    Int J Fertil Womens Med; 2005; 50(6):281-4. PubMed ID: 16526420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series.
    Hagen AI; Kvistad KA; Maehle L; Holmen MM; Aase H; Styr B; Vabø A; Apold J; Skaane P; Møller P
    Breast; 2007 Aug; 16(4):367-74. PubMed ID: 17317184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-risk screening: multi-modality surveillance of women at high risk for breast cancer (proven or suspected carriers of a breast cancer susceptibility gene).
    Kuhl CK
    J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):103-6. PubMed ID: 12585663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
    Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ
    J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of MRI screening for breast cancer in high-risk patients with LCIS and atypical hyperplasia.
    Port ER; Park A; Borgen PI; Morris E; Montgomery LL
    Ann Surg Oncol; 2007 Mar; 14(3):1051-7. PubMed ID: 17206485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study.
    Rijnsburger AJ; Obdeijn IM; Kaas R; Tilanus-Linthorst MM; Boetes C; Loo CE; Wasser MN; Bergers E; Kok T; Muller SH; Peterse H; Tollenaar RA; Hoogerbrugge N; Meijer S; Bartels CC; Seynaeve C; Hooning MJ; Kriege M; Schmitz PI; Oosterwijk JC; de Koning HJ; Rutgers EJ; Klijn JG
    J Clin Oncol; 2010 Dec; 28(36):5265-73. PubMed ID: 21079137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reasons for risk-reducing mastectomy versus MRI-screening in a cohort of women at high hereditary risk of breast cancer.
    Haroun I; Graham T; Poll A; Sun P; Hill K; Weitzner E; Narod S; Warner E
    Breast; 2011 Jun; 20(3):254-8. PubMed ID: 21306899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stage of breast cancers found during the surveillance of women with a familial or hereditary risk.
    Kaas R; Muller SH; Hart AA; Rutgers EJ
    Eur J Surg Oncol; 2008 May; 34(5):501-7. PubMed ID: 17555911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.